Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes

Journal of Experimental Medicine

Volumn 188, Issue 9, 1998, Pages 1641-1650

  Romero, Pedro ^a,b   Dunbar, P Rod ^c   Valmori, Danila ^a   Pittet, Mikaël ^a   Ogg, Graham S ^c   Rimoldi, Donata ^a   Chen, Ji Li ^c   Liénard, Danielle ^a,b   Cerottini, Jean Charles ^a   Cerundolo, Vincenzo ^c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Immunotherapy; Melan A MART 1; Melanoma; Tumor immunity; Tyrosinase

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPH NODE CELL; LYMPH NODE METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

EID: 0032476616     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.9.1641     Document Type: Article

References (22)

1. Robbins, P.F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628-636.
2. Romero, P. 1996. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Springer Semin. Immunopathol. 18:185-198.
3. Romero, P., J.C. Cerottini, and G. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T cell responses in cancer immunotherapy. Mol. Med. Today. 4:305-312.
4. Altman, J.D., P.A.H. Moss, P.J.R. Goulder, D.H. Barouch, M.G. McHeyzer-Williams, J.I. Bell, A.J. McMichael, and M.M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.
5. Dunbar, P.R., G.S. Ogg, J. Chen, N. Rust, P. van der Bruggen, and V. Cerundolo. 1998. Direct isolation, phenotyping and cloning of low frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol. 8: 413-416.
6. Parham, P., and F.M. Brodsky. 1981. Partial purification and some properties of BB7.2, a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3:277-284.
7. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wölfel, D. Liénard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/ MART-1 antigenic peptide in melanoma. J. Immunol. 159: 2366-2374.
8. Valmori, D., J.F. Fonteneau, C. Marañón Lizana, N. Gervois, D. Liénard, D. Rimoldi, C.V. Jongeneel, F. Jotereau, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/ MART-1 immunodominant peptide analogs. J. Immunol. 160:1750-1758.
9. Ogg, G.S., X. Jin, S. Bonhoeffer, P.R. Dunbar, M.A. Nowak, S. Monard, J.P. Segal, Y. Cao, S.L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:2103-2106.
10. Mulcahy, K.A., D. Rimoldi, F. Brasseur, S. Rodgers, D. Liénard, M. Marchand, I.G. Rennie, A.K. Murray, C.A. McIntyre, K.E. Platts, et al. 1996. Infrequent expression of the MAGE gene family in uveal melanomas. Int. J. Cancer. 66:738-742.
11. Smith, B., P. Selby, J. Southgate, K. Pittman, C. Bradley, and G.E. Blair. 1991. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 338:1227-1229.
12. Skipper, J.C.A., R.C. Hendrickson, P.H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wölfel, C.L. Slingluff, Jr., T. Boon, et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183:527-534.
13. bright T cell subsets and their relationship to memory and naive T cells. Eur. J. Immunol. 27:2383-2390.
14. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.F. Robbins, A. Sette, E. Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
15. Mazzocchi, A., W.J. Storkus, C. Traversari, P. Tarsini, M.J. Maeurer, L. Rivoltini, C. Vegetti, F. Belli, A. Anichini, G. Parmiani, and C. Castelli. 1996. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J. Immunol. 157: 3030-3038.
16. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:175-182.
17. Yee, C., S.R. Riddell, and P.D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702-708.
18. Ferrone, S., and F.M. Marincola. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today. 16: 487-494.
19. de Vries, T.J., A. Fourkour, T. Wobbes, G. Verkroost, D.J. Ruiter, and G.N. van Muijen. 1997. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57:3223-3229.
20. Cormier, J.N., Y.M. Huazi, A. Abati, P. Fetsch, M. Bettinotd, S.M. Steinberg, S.A. Rosenberg, and F.M. Marincola. 1998. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer. 75:517-524.
21. Mizoguchi, H., J.J. O'Shea, D.L. Longo, C.M. Loeffler, D.W. McVicar, and A.C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1795-1798.
22. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Liénard, et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363-1366.